Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: A meta-analysis of randomised controlled trials

EuroIntervention

Volumn 5, Issue 3, 2009, Pages 384-393

  Tamhane, Umesh ^a   Meier, Pascal ^a   Chetcuti, Stanley ^a   Chen, Kang Yin ^b   Rha, Seung Woon ^c   Grossman, Michael P ^a   Gurm, Hitinder ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^c Korea University College of Medicine   (South Korea)

Author keywords

Angioplasty; Cilostazol; Coronary flow; Drug delivery

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; THIENOPYRIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; METAL; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; BLEEDING; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ERUPTION; DRUG RESPONSE; HUMAN; IN-STENT RESTENOSIS; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; STENT THROMBOSIS; SYSTEMATIC REVIEW; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG COMBINATION; FEMALE; INSTRUMENTATION; MALE; MIDDLE AGED; PROSTHESIS; PUBLISHING; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; RISK; STENT; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; EXANTHEMA; FEMALE; HEMORRHAGE; HUMANS; MALE; METALS; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; PUBLICATION BIAS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STENTS; TETRAZOLES; THROMBOSIS; TREATMENT OUTCOME;

EID: 70349787228     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/V5I3A60     Document Type: Article

References (55)

1. Douglas JS, Jr., Holmes DR, Jr., Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826-2832. (Pubitemid 41641677)
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. The New England Journal of Medicine. 2003;349:1315-1323. (Pubitemid 37186209)
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. The New England Journal of Medicine. 2004;350:221-231. (Pubitemid 38067635)
4. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008;51:1181-1187. (Pubitemid 351382092)
5. Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, Nobuyoshi M. Efficacy of Cilostazol After Endovascular Therapy for Femoropopliteal Artery Disease in Patients With Intermittent Claudication. J Am Coll Cardiol. 2009;53:48-53.
6. Biondi-Zoccai GG, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, Abbate A, Cosgrave J, Laudito A, Trevi GP, Sheiban I. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J. 2008;155:1081-1089.
7. Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol. 2005;34:224-225; author reply 225.
8. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-1060. (Pubitemid 29436453)
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. (Pubitemid 37088507)
10. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315:629-634. (Pubitemid 27387172)
12. Orwin R. A fail-safe N for effect size in meta-analysis. J Educ Stat. 1983;8:157-159.
13. Rosenberg MS. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. Evolution Int J Org Evolution. 2005;59:464-468. (Pubitemid 40356057)
14. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463. (Pubitemid 30422636)
15. Han YL, Su QF, Li Y, Wang SL, Jing QM, Ma YY, Wang ZL, Wang DM, Luan B. [Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention]. Zhonghua Yi Xue Za Zhi. 2006;86:1093-1096.
16. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46:1833-1837. (Pubitemid 41579804)
17. Park SW. DECREASE: A Prospective Registry Examining the Safety and Efficacy of Triple Antiplatelet Therapy After Drug-Eluting Stent Implantation. Presented at the Transcatheter Cardiovascular Therapeutics 20th Annual Scientific Symposium Washington, DC, October 2008. http://www.tctmd.com/txshow. aspx?tid=2432&id=69996&trid=2380 (Accessed December 25, 2008).
18. Chen KY, Rha SW, Li YJ, Poddar KL, Park JH, Na JO, Choi CU, Lim HE, Kim JW, Kim EJ, Park CG, Seo HS, Oh DJ, Ahn YK, Jeong MH. Triple versus Dual Antiplatelet Therapy in Patient with Acute ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Am J Cardiol, Suppl 2008;102:35i.
19. Yamasaki M, Hara K, Ikari Y, Kobayashi N, Kozuma K, Ohmoto Y, Oh-Hashi Y, Ako J, Nakajima H, Chiku N, Saeki F, Tamura T. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn. 1998;44:387-391. (Pubitemid 28359961)
20. Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, So T, Nakamura T, Oohama N, Murayama M. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther. 1997;19:1058-1066. (Pubitemid 27508940)
21. Ge J, Han Y, Jiang H, Sun B, Chen J, Zhang S, Du Z. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. J Cardiovasc Pharmacol. 2005;46:162-166. (Pubitemid 41060208)
22. Yoon Y, Shim WH, Lee DH, Pyun WB, Kim IJ, Jang Y, Cho SY. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol. 1999;84:1375-1380.
23. Park SW, Lee CW, Kim HS, Lee NH, Nah DY, Hong MK, Kim JJ, Park SJ. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86:499-503.
24. Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, Takayanagi K, Morooka S. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J. 2002;144:303-308. (Pubitemid 34879655)
25. Kozuma K, Hara K, Yamasaki M, Morino Y, Ayabe S, Kuroda Y, Tanabe K, Ikari Y, Tamura T. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J. 2001;141:124-130. (Pubitemid 32061322)
26. Ochiai M, Eto K, Takeshita S, Yokoyama N, Oshima A, Kondo K, Sato T, Isshiki T. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. Am J Cardiol. 1999;84:1074-1076, A1076, A1079.
27. Sekiguchi M, Hoshizaki H, Adachi H, Ohshima S, Taniguchi K, Kurabayashi M. Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol. Circ J. 2004;68:610-614. (Pubitemid 38899592)
28. Song JH, Yoon C, Rhee I, Jung JY, Jo KH, Kim DI, Kim DS. A Randomized Comparison of Cilostazol Versus Ticlopidine Therapy After Elective Coronary Stent Implantaion. Korean Circ J. 2001;31:780-787.
29. Takeyasu N, Watanabe S, Noguchi Y, Ishikawa K, Fumikura Y, Yamaguchi I. Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. Circ J. 2005;69:780-785. (Pubitemid 40994281)
30. Han Y, Wang S, Li Y, Jing Q, Ma Y, Deng J, Yang G, Yu H, Ge J. Cilostazol improves long-term outcomes after coronary stent implantation. Am Heart J. 2005;150:568.
31. Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y, Ozaki Y, Hikichi Y, Node K. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol. 2004;44:1408-1414. (Pubitemid 39303941)
32. Tsutsui M, Shimokawa H, Higuchi S, Yoshihara S, Hayashida K, Sobashima A, Kuga T, Matsuguchi T, Okamatsu S. Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J. 1996;60:207-215.
33. Take S, Matsutani M, Ueda H, Hamaguchi H, Konishi H, Baba Y, Kawaratani H, Sugiura T, Iwasaka T, Inada M. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1997;79:1097-1099. (Pubitemid 27217066)
34. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21-26. (Pubitemid 29297935)
35. Nagaoka N, Matsubara T, Okazaki K, Masuda N, Shikaura K, Hotta A. Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J. 2001;42:43-54. (Pubitemid 32241771)
36. Tsuchikane E, Katoh O, Sumitsuji S, Fukuhara A, Funamoto M, Otsuji S, Tateyama H, Awata N, Kobayashi T. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J. 1998;135:495-502. (Pubitemid 28125687)
37. Jeong Y-H, Choi B-R, Kim I-S, Kwak CH, Hwang J-Y, Lee S-W, Park S-W. Abstract 2014: Additive Cilostazol to Dual Antiplatelet Therapy Achieves Greater Inhibition of Platelet Aggregation Compared With High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction. Circulation. 2008;118(18-MeetingAbstracts):S-657-b.
38. Lee BK, Lee SW, Park SW, Park DW, Kim YH, Lee CW, Hong MK, Kim JJ, Jang S, Chi HS, Park SJ. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol. 2007;100:610-614. (Pubitemid 47223135)
39. Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Guzman LA, Bass TA. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. European Heart Journal. 2008;29:2202-2211.
40. Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J. 2007;71:1867-1872. (Pubitemid 350261408)
41. Han Y, Li Y, Wang S, Jing Q, Wang D, Wang Z, Tang X. Triple Antiplatelet Therapy Improves Long-term Outcomes After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes. Am J Cardiol. 2007;100:S33.
42. Chen YD, Lu YL, Jin ZN, Yuan F, Lu SZ. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl). 2006;119:360-366. (Pubitemid 43796888)
43. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100:1103-1108. (Pubitemid 47404466)
44. Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. Circ J. 2007;71:1685-1690. (Pubitemid 350240086)
45. Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, Park CG, Kim JH, Chae IH, Nam CW, Hur SH, Bae JH, Kim KY, Oh SK. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients-cilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J. 2008;72:35-39. (Pubitemid 351413323)
46. Kim DH, Kim JY, Moon SW, Jung JH, Yang HS, Cho JH, Jeong MH. Effects of long-term triple anti-platelet therapy with low-dose cilostazol after drug-eluting stent implantation. Korean J Med. 2008;74:368-375.
47. Hong SJ, Park CG, Choi JI, Shim WJ, Park SM, Lim SY, Lim DS. Effects of Cilostazol on Carotid Intima-Media Thickness in Patients with Acute Coronary Syndrome. Am J Cardio. 2008;101:S1-S108.
48. Jeong JW, Shim DS, Moon JY, Yoon NS, Yoon HJ, Kim KH, ParkHW, Hong YJ, Kim JH, Jeong MH, Cho JG, Park JC, Ahn Y. The Effects of Cilostazol on 6-Month Angiographic and 1-Year Clinical Outcomes in Patients with Diabetes Who Underwent Drug-Eluting Stent Implantation. Am J Cardio. 2008;101:S1-S108.
49. Long-DES-II Study Investigators. Percutaneous Treatment of LONG native Coronary Lesions with Drug-Eluting Stent-II: Cypher versus Taxus, Long-DES II study. Available on crtonline.org (http://www.crtonline.org/flash.aspx?PAGE-ID= 3397) Accessed on January 2009.
50. Morishita R. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atherosclerosis. Supplements. 2005;6:41-46.
51. Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation. 2003;107:1757-1763. (Pubitemid 36418356)
52. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151:1260-1264. (Pubitemid 43866610)
53. Nayak AK, Kawamura A, Nesto RW, Davis G, Jarbeau J, Pyne CT, Gossman DE, Piemonte TC, Riskalla N, Chauhan MS. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J. 2006;70:1026-1029. (Pubitemid 44161740)
54. Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, Schomig A. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J. 2004;147:317-322. (Pubitemid 38176833)
55. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233. (Pubitemid 17137858)